Related references
Note: Only part of the references are listed.Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
David Cook et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium
Philip Sager et al.
AMERICAN HEART JOURNAL (2013)
Revolution dawning in cardiotoxicity testing
Kelly Rae Chi
NATURE REVIEWS DRUG DISCOVERY (2013)
Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human
Joanna Parkinson et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2013)
The ability of animal studies to detect serious post marketing adverse events is limited
Peter J. K. van Meer et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2012)
Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the Safety Pharmacology Society
D. J. Leishman et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2012)
How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?
H. G. Laverty et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development
F. Peter Guengerich
DRUG METABOLISM AND PHARMACOKINETICS (2011)
Cardiovascular safety assessments in the conscious telemetered dog: Utilisation of super-intervals to enhance statistical power
A. Sivarajah et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2010)
Lessons from 60 years of pharmaceutical innovation
Bernard Munos
NATURE REVIEWS DRUG DISCOVERY (2009)
A framework to assess the translation of safety pharmacology data to humans
Jean-Pierre Valentin et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2009)
Discordant effects of β-blockade on central aortic systolic and brachial systolic blood pressure:: Considerations beyond the cuff
Benjamin J. Epstein et al.
PHARMACOTHERAPY (2007)
A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data
DM Jonker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
First dose of potential new medicines to humans: How animals help
P Greaves et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Ruling a diagnosis in or out with SpPIn and SnNOut: a note of caution
D Pewsner et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Refinements in telemetry procedures - Seventh report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement, part A
DB Morton et al.
LABORATORY ANIMALS (2003)
Understanding sensitivity and specificity with the right side of the brain
TW Loong
BMJ-BRITISH MEDICAL JOURNAL (2003)
Central challenges facing the national clinical research enterprise
NS Sung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Concordance of the toxicity of pharmaceuticals in humans and in animals
H Olson et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2000)
Share Paper
